The ABBV chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ABBV chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ABBV stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
View ABBV Detailed Price Forecast - CNN Money | View ABBV Detailed Summary - Google Finance | ||
View ABBV Detailed Summary - Yahoo! Finance | View ABBV Stock Research & Analysis - Zacks.com |
View ABBV Trends & Analysis - Trade-Ideas | View ABBV Major Holders - Barrons | ||
View ABBV Call Transcripts - NASDAQ | View ABBV Breaking News & Analysis - Seeking Alpha | ||
View ABBV Annual Report - CompanySpotlight.com | View ABBV OTC Short Report - OTCShortReport.com | ||
View ABBV Fundamentals - TradeKing | View ABBV SEC Filings - Bar Chart | ||
View Historical Prices for ABBV - The WSJ | View Performance/Total Return for ABBV - Morningstar | ||
View the Analyst Estimates for ABBV - MarketWatch | View the Earnings History for ABBV - CNBC | ||
View the ABBV Earnings - StockMarketWatch | View ABBV Buy or Sell Recommendations - MacroAxis | ||
View the ABBV Bullish Patterns - American Bulls | View ABBV Short Pain Metrics - ShortPainBot.com |
View ABBV Stock Mentions - StockTwits | View ABBV Stock Mentions - PennyStockTweets | ||
View ABBV Stock Mentions - Twitter | View ABBV Investment Forum News - Investor Hub | ||
View ABBV Stock Mentions - Yahoo! Message Board | View ABBV Stock Mentions - Seeking Alpha |
View Insider Transactions for ABBV - SECform4.com | View Insider Transactions for ABBV - Insider Cow | ||
View ABBV Major Holdings Summary - CNBC | View Insider Disclosure for ABBV - OTC Markets | ||
View Insider Transactions for ABBV - Yahoo! Finance | View Institutional Holdings for ABBV - NASDAQ |
View ABBV Stock Insight & Charts - FinViz.com | View ABBV Investment Charts - StockCharts.com | ||
View ABBV Stock Overview & Charts - BarChart | View ABBV User Generated Charts - Trading View |
Cigna to offer Humira rivals with $0 copay at specialty pharmacy
Posted on Thursday April 25, 2024
Cigna plans to make close copies of AbbVie's blockbuster arthritis drug Humira available with no out-of-pocket payment to eligible patients in the U.S. using its specialty pharmacy beginning in June, the health insurer said on Thursday. Cigna said it will stock high- and low-concentration biosimilar versions of Humira from drugmakers including Boehringer Ingelheim, Teva and Alvotech at its Accredo pharmacy.
UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
Posted on Thursday April 25, 2024
AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals and Sanofi's Dupixent in a late-stage head-to-head study. Rinvoq helped 19.9% of patients simultaneously achieve near-complete skin clearance with a no-to-little itch after 16 weeks of treatment, compared with 8.9% of patients treated with Dupixent, the study showed. The study is the first head-to-head trial in adults and adolescents with moderate-to-severe atopic dermatitis and had shown an inadequate response to systemic therapy, AbbVie said.
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie
Posted on Thursday April 25, 2024
Eli Lilly, Novo Nordisk, Merck and AbbVie are part of the Zacks Industry Outlook article.
New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study
Posted on Thursday April 25, 2024
AbbVie (NYSE: ABBV) today announced positive topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase 3b/4 study that evaluated the efficacy and safety of upadacitinib (RINVOQ®, 15 mg once daily starting dose and dose-adjusted based on clinical response) versus dupilumab (DUPIXENT®, per its labeled dose) in adults and adolescents (≥12 years of age) with moderate-to-severe atopic dermatitis (AD) who had an inadequate response to systemic therapy or when use of th